Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (NASDAQ: QSI) drives innovation in proteomics through its revolutionary single-molecule detection platform. This dedicated news hub provides investors and researchers with timely updates on the company's advancements in next-generation protein sequencing technology.
Access authoritative updates including product developments, strategic partnerships, and financial disclosures. Our curated collection ensures efficient tracking of QSI's progress in creating integrated hardware-software solutions for biomolecular analysis.
Key coverage areas: platform innovations enhancing protein detection accuracy, research collaborations advancing life sciences, and operational milestones shaping the future of proteomics tools. All content is verified through primary sources to ensure reliability.
Bookmark this page for streamlined access to Quantum-Si's latest developments in transformative protein sequencing solutions. Check regularly for updates that matter to both scientific and investment communities.
Quantum-Si (Nasdaq: QSI) announced its first-quarter financial results for 2022, reporting a net loss of $35.2 million, up from $11.8 million in Q1 2021. Research and development expenses increased significantly to $18.8 million, driven by higher personnel costs. The company held $434.8 million in cash and marketable securities, ensuring adequate funding for future initiatives. Quantum-Si also made progress in technology transfer and announced the appointment of Patrick Schneider as President & COO, aiming for a launch in the second half of 2022.
Quantum-Si Incorporated (NASDAQ: QSI) appointed Patrick Schneider, Ph.D., as President and COO, succeeding Michael McKenna, who will stay on as Executive VP of Product Development. Schneider brings over 25 years of experience in life sciences, previously serving at MilliporeSigma, where he oversaw strategy and business development. Interim CEO Jonathan Rothberg expressed confidence in Schneider's leadership to drive the company's ambitious plans for next-generation protein sequencing. Quantum-Si aims to revolutionize proteomics with its innovative semiconductor chip technology.
Tesseract Health has appointed Michael McConnell, MD, MSEE, as Head of Cardiovascular and Digital Health, strengthening its leadership under CEO Vicky Demas. Dr. McConnell brings expertise from Google Health and aims to guide the development of cardiovascular health products using Tesseract's non-invasive technology. The company is focused on democratizing health screening and aims to innovate ocular health diagnostics. Tesseract is part of 4Catalyzer, which includes companies like Butterfly Network (NYSE: BFLY), Quantum-Si (NASDAQ: QSI), and Hyperfine (NASDAQ: HYPR).
Quantum-Si Incorporated (NASDAQ: QSI), a leader in single molecule protein sequencing, will disclose its first quarter 2022 financial results post-market on May 9, 2022. A conference call for discussing these results and providing a business update is scheduled for 4:30 p.m. ET on the same day. The company's innovative technologies aim to transform proteomics by utilizing a unique semiconductor chip to enhance drug discovery and diagnostics.
Quantum-Si Incorporated (NASDAQ: QSI) announced participation in the B. Riley Disruptive Biotech Enabling Technologies Virtual Mini Conference. Scheduled for April 7, 2022, at 10:20 am ET, the presentation will focus on the company's innovative approach to single molecule protein sequencing aimed at revolutionizing proteomics and advancing drug discovery. Interested listeners should contact their B. Riley Securities representatives for access. Quantum-Si’s technology leverages a unique semiconductor chip for enhanced proteomic research.
Quantum-Si (Nasdaq: QSI) reported its Q4 and fiscal year 2021 results, revealing significant increases in operating expenses totaling $27.8 million in Q4, leading to a net loss of $29.4 million. For the fiscal year, total net loss reached $95.0 million, up from $36.6 million in 2020. The company ended the year with $471.3 million in cash and equivalents, positioning it well for upcoming product launches in 2022. They formed a new Scientific Advisory Board, expanded staff from 72 to 153, and entered strategic partnerships to enhance research applications.
Quantum-Si (NASDAQ: QSI) announced its participation in the 42nd Annual Cowen Health Care Conference, scheduled for March 8, 2022, at 2:10 pm ET. The presentation will be held virtually, and interested parties can access a live webcast on the Quantum-Si investor website. A replay will be available post-event. Quantum-Si is pioneering the field of proteomics with its innovative semiconductor chip that enables single molecule protein sequencing, advancing drug discovery and diagnostics.
Quantum-Si (NASDAQ: QSI) announced the appointment of Dr. Jonathan Rothberg as Interim CEO, effective February 8, 2022. Dr. Rothberg, founder and Executive Chairman, will lead the company during the transition as it searches for a permanent CEO. Quantum-Si focuses on revolutionary single molecule protein sequencing, similar to the impact of DNA sequencing in oncology. The company aims to commercialize its groundbreaking technology in 2022, emphasizing its importance in understanding immune responses to COVID-19. Financial results for Q4 and full year 2021 will be reported on February 28, 2022.
Quantum-Si Incorporated (Nasdaq: QSI) will report fourth quarter and full year 2021 financial results after market close on February 28, 2022. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. Quantum-Si focuses on commercializing a unique single molecule protein sequencing platform, aiming to revolutionize proteomics and advance drug discovery. Founded in 2013 by Dr. Jonathan Rothberg, the company utilizes an innovative semiconductor chip designed for next-generation protein sequencing.
Quantum-Si Incorporated (Nasdaq: QSI) announced key updates ahead of the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. They established list prices for their protein sequencing platform: $70,000 for the PlatinumTM Analyzer and $20,000 for the CarbonTM sampler, with pre-orders starting in H1 2022. The company also published a technical manuscript on bioRxiv, detailing advancements in single-molecule protein sequencing. CEO John Stark emphasized the company's growth momentum and plans for commercialization in 2022.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
